Understand the source comparison
SS-LUP-332 Oral vs Injectable: Route Comparison
The table below compares SS-LUP-332 oral vs injectable across bioavailability, onset, dosing, and practical research factors. Bioavailability 15–25% (gastric degradation + first-pass metabolism) 95–100% (bypasses GI tract and liver) Injectable delivers 3–5× hi
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares SS-LUP-332 oral vs injectable across bioavailability, onset, dosing, and practical research factors.
- Bioavailability
- 15–25% (gastric degradation + first-pass metabolism)
- 95–100% (bypasses GI tract and liver)
- Injectable delivers 3–5× higher plasma concentration at equivalent doses
- Onset of Action
- 90–150 minutes (depends on gastric emptying)
- 30–60 minutes (direct systemic absorption)
- Injectable produces measurable effects 2–3× faster
- Peak Plasma Concentration
- Lower and more variable (affected by food, pH)
- Higher and more predictable (minimal variability)
- Injectable provides more consistent experimental conditions
- Typical Dose Range
- 10–50 mg (compensates for low absorption)
- 2–10 mg (higher bioavailability = lower dose needed)
- Oral requires 3–5× higher dose to approximate injectable plasma levels
- Storage Requirements
- Room temperature stable (15–25°C, 12–24 months)
- Lyophilised: −20°C; reconstituted: 2–8°C, 28 days
- Oral formulations simplify storage logistics
- Administration Complexity
- Simple (oral ingestion, no special technique)
- Moderate (requires sterile technique, injection training)
- Oral is faster and easier for large-scale studies
- Metabolic Effect Magnitude
- Moderate (blunted by low bioavailability)
- High (full dose reaches target tissues)
- Injectable produces stronger thermogenic response at lower doses
- Safety Margin
- Wider (most of dose never reaches circulation)
- Narrower (nearly all administered dose is bioavailable)
- Oral formulations are more forgiving of dosing errors